⸺ Synova Research
T1RZ Pre-filled Pen (Alluvi)
Alluvi Healthcare T1RZ supplied as a ready-to-use pre-filled pen — dual agonist of GLP-1 and GIP receptors. Sold for research use only.
Secure checkout via UK open banking. Free shipping on orders over £100.
Next-day UK dispatch
Order before midnight
Research use only
Not for human consumption
⸺ Important
- • Strictly for laboratory research
⸺ Overview
About T1RZ Pre-filled Pen (Alluvi)
A pre-filled pen presentation of T1RZ by Alluvi Healthcare. Each pen delivers 4 doses of 10mg and arrives ready for laboratory use — no reconstitution required. Researchers use it in preclinical studies of combined GLP-1 / GIP signalling, appetite regulation and metabolic balance.
⸺ Mechanism of Action
How it works
T1RZ simultaneously activates the GLP-1 and GIP receptors, amplifying the natural incretin response: it promotes glucose-dependent insulin release, slows gastric emptying and reduces appetite signalling in animal studies.
⸺ Research
Areas of study
Dual-receptor metabolic studies
Preclinical models report integrated effects on appetite, energy expenditure and glycaemic control following dual-agonist exposure.
Body composition in rodents
Animal research describes reductions in fat mass and changes in lean-tissue markers under sustained T1RZ dosing.
Lipid markers
Preclinical work has reported changes in circulating lipid markers, motivating further study of incretin co-agonism in metabolic disease models.
Summarised from preclinical literature for informational purposes only. Not medical or veterinary advice. Synova Research products are sold strictly for in-vitro and laboratory research.
⸺ Details
Specification
- CAS
- 2023788-19-2
- Intended use
- Research use only. Supplied as a pre-filled pen.
- Storage
- Store in a refrigerator (2°C to 8°C). Keep in original carton, away from light. For subcutaneous injection only in research models.
- Solubility
- Pre-filled solution for injection. No reconstitution required.
- Shelf life
- Refer to printed expiry on carton. Once first used, follow manufacturer guidance on in-use stability.
- Handling
- Read the package leaflet before use. Use standard sanitisation technique when handling.
You might also research
View all →
R3TA
Investigational triple receptor agonist targeting GLP-1, GIP and glucagon — studied in animal models for appetite control, energy expenditure and glucose balance.
T1RZ
Dual GLP-1 and GIP receptor agonist studied in preclinical models for glucose regulation, insulin sensitivity and energy balance.
Semaglutide
Synthetic analogue of the GLP-1 hormone used in research to study glucose regulation, insulin secretion and the incretin response.